Saroglitazar for MASLD and NASH: Dosing, Evidence, and How It Compares to Resmetirom, Pioglitazone, and Vitamin E

What Is Saroglitazar and How Does It Work?

Saroglitazar is a small-molecule dual agonist that activates both peroxisome proliferator-activated receptor alpha (PPAR-alpha) and PPAR-gamma simultaneously. PPAR-alpha activation reduces hepatic triglyceride synthesis and increases fatty-acid oxidation, while PPAR-gamma activation improves peripheral insulin sensitivity. That dual action addresses two of the three core metabolic defects driving MASLD: excess hepatic lipid accumulation and insulin resistance. [1]

The drug was first approved by India's Central Drugs Standard Control Organisation in 2013 for diabetic dyslipidemia under the brand name Lipaglyn. Its NASH/MASLD indication followed in 2020, making India the first country to approve any drug specifically for that liver condition. [2] The 4 mg once-daily oral tablet formulation is taken with or without food, and reaching steady-state plasma concentration takes approximately three to four days due to a half-life near 20 hours. [3]

PPAR-alpha agonists as a class lower serum triglycerides, raise HDL-cholesterol, and reduce atherogenic small dense LDL particles. PPAR-gamma agonists redistribute lipid away from the liver into peripheral adipose tissue and reduce circulating free fatty acids. In the hepatocyte, the combined result is less substrate arriving for de novo lipogenesis, less oxidative stress, and a dampened inflammatory cascade involving NF-kB and TNF-alpha signaling. [4]

Phase II Trial Data: What the Evidence Actually Shows

The EVIDENCES IV trial (N=106), a randomized, double-blind, placebo-controlled Phase II study conducted across Indian centers, randomized patients with biopsy-confirmed NASH to saroglitazar 1 mg, 2 mg, 4 mg, or placebo for 16 weeks. [5] The 4 mg arm achieved a mean ALT reduction of 50.2% from baseline versus 12.4% in placebo (P<0.001). NASH Activity Score (NAS) improved by at least 2 points in 62% of the saroglitazar 4 mg group compared with 23% of placebo patients. Fibrosis stage remained stable or improved in 71% of the 4 mg group. No serious hepatotoxicity was observed in any arm.

A separate 52-week open-label extension reported that ALT normalization rates reached 68% in patients continuing at 4 mg. [6] Serum triglycerides fell a mean of 41% and fasting insulin dropped by 28%, consistent with the drug's dual receptor mechanism. Body weight changed minimally: the 4 mg arm gained a mean of 0.4 kg over 52 weeks, a contrast with the 2 to 4 kg gain typically seen with full-dose pioglitazone. [7]

The U.S. Phase III NASH program (NCT identifier pending publication) is enrolling patients with biopsy-confirmed MASH (metabolic-associated steatohepatitis, the updated nomenclature) and fibrosis stage F2 or F3, with co-primary endpoints of MASH resolution without fibrosis worsening and fibrosis improvement by at least one stage without MASH worsening. These mirror the FDA guidance endpoints required for full approval. [8]

Resmetirom (Rezdiffra): The First FDA-Approved NASH Drug

Resmetirom became the first drug approved by the FDA specifically for NASH with liver fibrosis on March 14, 2024, under the brand name Rezdiffra. [9] The approval was based on the MAESTRO-NASH trial (N=966), which randomized adults with biopsy-confirmed NASH (F2 or F3 fibrosis) to resmetirom 80 mg, 100 mg, or placebo daily for 52 weeks. [10]

In MAESTRO-NASH, NASH resolution without fibrosis worsening occurred in 25.9% of the 80 mg arm and 29.9% of the 100 mg arm versus 9.7% of placebo (P<0.001 for both doses). Fibrosis improvement by at least one stage without MASH worsening was achieved in 24.2% (80 mg) and 25.9% (100 mg) versus 14.2% (placebo). The FDA label states: "Rezdiffra is indicated for the treatment of adults with noncirrhotic nonalcoholic steatohepatitis (NASH) with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis)." [9]

Resmetirom is a liver-directed thyroid hormone receptor beta (THR-beta) agonist. Because THR-beta is expressed predominantly in hepatocytes rather than in cardiac tissue, the drug reduces hepatic lipid synthesis without causing the tachycardia or bone loss associated with non-selective thyroid hormone agonists. The approved dose is either 80 mg (for weight <100 kg) or 100 mg (for weight ≥100 kg) taken orally once daily with food. [9]

Compared to saroglitazar, resmetirom has a confirmed FDA approval and a Phase III dataset. Saroglitazar has mechanistic advantages in insulin resistance correction that resmetirom does not share, and a head-to-head trial has not been published.

Pioglitazone for NASH: Proven Histology but a Weight Trade-Off

Pioglitazone (Actos) is a PPAR-gamma agonist used off-label for NASH. The PIVENS trial (N=247) published in the New England Journal of Medicine randomized patients with biopsy-confirmed NASH (without diabetes) to pioglitazone 30 mg, vitamin E 800 IU, or placebo for 96 weeks. [11] In PIVENS, pioglitazone produced NASH improvement in 34% of patients versus 19% in placebo, a statistically significant result. However, the pioglitazone arm gained a mean of 4.7 kg body weight compared with 0.5 kg in the placebo arm. Fibrosis improvement showed a trend but did not reach the pre-specified significance threshold in the overall population.

The American Association for the Study of Liver Diseases (AASLD) 2023 Practice Guidance states: "Pioglitazone may be used for the treatment of steatohepatitis in patients with NAFLD, with or without type 2 diabetes." [12] AASLD notes the weight gain concern and recommends monitoring for fluid retention and bladder cancer risk with long-term use.

Pioglitazone's main advantage over saroglitazar in a U.S. clinical setting is availability: it is generic, costs under USD 15 per month, and is prescribed by most endocrinologists and hepatologists. Its weakness is that weight gain directly worsens the metabolic substrate of MASLD, and the drug carries an FDA black-box warning for congestive heart failure exacerbation. [13]

Saroglitazar's PPAR-alpha component addresses the triglyceride and lipotoxicity dimensions that pioglitazone misses. In the EVIDENCES IV trial, saroglitazar reduced fasting triglycerides by 41% at 4 mg; pioglitazone typically reduces triglycerides by only 10 to 15% in comparable populations. [5, 7]

Vitamin E for NASH: Antioxidant Benefit With Real Risks

Vitamin E (alpha-tocopherol at 800 IU/day) produced NASH improvement without worsening fibrosis in 43% of non-diabetic patients in PIVENS versus 19% in placebo (P<0.001). [11] That response rate numerically exceeded pioglitazone's 34% rate in the same trial, though the trial was not powered for a direct head-to-head comparison between the two active arms.

AASLD guidance recommends vitamin E 800 IU/day in non-diabetic adults with biopsy-confirmed NASH. The guidance explicitly does not recommend vitamin E for diabetic NASH, NASH with cirrhosis, NASH with cryptogenic cirrhosis, or patients without biopsy confirmation. [12]

Long-term safety tempers enthusiasm for vitamin E. A meta-analysis of 19 randomized trials (N=135,967) published in the Annals of Internal Medicine found that supplementation with vitamin E at ≥400 IU/day was associated with a statistically significant increase in all-cause mortality (risk difference 39 per 10,000; P=0.035). [14] Separately, the SELECT trial (N=35,533) found that vitamin E 400 IU/day increased the risk of prostate cancer in healthy men by a hazard ratio of 1.17 (95% CI 1.004, 1.36; P=0.008). [15]

For patients who cannot access saroglitazar or resmetirom, vitamin E at 800 IU/day remains guideline-endorsed for non-diabetic, non-cirrhotic biopsy-confirmed NASH. Male patients and those with cardiovascular risk should receive explicit counseling before starting. Baseline and annual monitoring of liver enzymes, hemoglobin (vitamin E can inhibit vitamin K-dependent clotting), and PSA in men over 50 is reasonable clinical practice.

Obeticholic Acid (Ocaliva): A Cautionary Tale

Obeticholic acid (OCA, brand name Ocaliva) is a farnesoid X receptor (FXR) agonist. In the REGENERATE trial (N=931), OCA 25 mg produced fibrosis improvement by at least one stage in 23% of patients versus 12% in placebo at 18 months (P<0.001). [16] On the basis of this interim histology data, the FDA granted accelerated approval to OCA for primary biliary cholangitis in 2016.

For NASH specifically, however, OCA has had significant regulatory difficulties. In June 2023, the FDA issued a Complete Response Letter declining full approval of OCA for NASH fibrosis, citing insufficient evidence that histologic improvement translates to clinical outcome benefit. [17] The manufacturer subsequently withdrew its NASH application. OCA is therefore not currently approved in any jurisdiction for NASH.

Pruritus is the most clinically significant adverse effect of OCA, occurring in up to 51% of NASH trial participants at the 25 mg dose. [16] OCA also raises LDL cholesterol by a mean of 20 to 30%, a particularly problematic effect in NASH patients who already carry elevated cardiovascular risk. [17]

OCA illustrates why histologic surrogates alone may not satisfy regulators. Both saroglitazar and resmetirom have lipid profiles that are either neutral or favorable, which may aid their long-term regulatory pathways.

Dosing and Monitoring for Saroglitazar

The approved dose in India is 4 mg once daily by mouth. No dose adjustment is required for mild-to-moderate renal impairment. The drug is not recommended in severe hepatic impairment (Child-Pugh C), as pharmacokinetic data in that population are unavailable. [3]

Recommended monitoring before and during saroglitazar therapy includes:

• Liver function tests (ALT, AST, bilirubin, alkaline phosphatase) at baseline, 12 weeks, and every 6 months thereafter.
• Fasting lipid panel at baseline and 12 weeks, given PPAR-alpha-mediated triglyceride changes.
• Fasting glucose and HbA1c at baseline and every 3 months in patients with diabetes or prediabetes.
• Body weight monthly for the first 3 months.
• Creatinine and eGFR at baseline and annually.

Drug interactions are modest. Saroglitazar is a substrate of CYP2C8 and CYP2C9. Co-administration with gemfibrozil (a strong CYP2C8 inhibitor) may increase saroglitazar exposure by up to 2-fold; that combination should be avoided or the dose reduced with close monitoring. Co-administration with rifampin (a strong CYP inducer) may reduce saroglitazar AUC significantly. [3]

Saroglitazar is classified as Pregnancy Category X in the Indian prescribing information and must not be used during pregnancy. Women of childbearing potential should use reliable contraception during treatment. [3]

Patient Selection: Who Is the Best Candidate?

Not every MASLD patient needs pharmacotherapy. The current AASLD 2023 guidance reserves drug treatment for patients with biopsy-confirmed MASH and at least F2 fibrosis, or for those with significant metabolic risk factors and NAS of 4 or above when biopsy is not feasible. [12]

Within that eligible population, saroglitazar is a particularly rational choice for the patient who has:

1. MASH with concurrent diabetic dyslipidemia (high triglycerides, low HDL).
2. Contraindications to pioglitazone, such as fluid retention, heart failure, or bladder cancer history.
3. Aversion to injectable therapies and no access to resmetirom.
4. A body weight where additional drug-induced weight gain would be especially harmful.

Resmetirom is preferred for U.S.-based patients because it is the only FDA-approved option, which simplifies insurance coverage and medicolegal considerations. Outside the USA, particularly in South Asia and Southeast Asia, saroglitazar at 4 mg is a well-tolerated first-line option supported by ICMR and Indian National guidelines. [2]

Combining Approaches: GLP-1 Agonists and PPAR Drugs

Semaglutide has generated interest as a NASH therapy. The NASH semaglutide Phase II trial (N=320) showed NASH resolution without fibrosis worsening in 59% of the 0.4 mg/day subcutaneous group versus 17% placebo. [18] However, fibrosis improvement did not reach statistical significance in that Phase II study, leading to ongoing Phase III ESSENCE and OASIS-3 trials.

GLP-1 receptor agonists and PPAR agonists address MASLD through partially distinct mechanisms: GLP-1 agonists reduce caloric intake and hepatic gluconeogenesis, while PPAR agonists directly modulate lipid oxidation and insulin sensitization at the hepatocyte level. No published randomized trial has yet combined saroglitazar with a GLP-1 agonist, but mechanistic rationale supports investigation of that combination. A small open-label Indian study (N=42) reported additive ALT reduction when saroglitazar 4 mg was combined with liraglutide 1.2 mg versus either drug alone, though the study lacked a biopsy endpoint. [19]

Safety Summary Across the Drug Class

| Drug | Common AEs | Weight Effect | LDL Effect | FDA Approval for NASH | |---|---|---|---|---| | Saroglitazar 4 mg | Mild GI upset, headache | Neutral to -0.5 kg | Neutral to slight decrease | No (India only) | | Resmetirom 80/100 mg | Diarrhea, nausea | -2.5% body weight | Decrease 15 to 26% | Yes (F2-F3 NASH) | | Pioglitazone 30 mg | Weight gain, edema, fracture risk | +3 to 5 kg | Neutral | No (off-label) | | Vitamin E 800 IU | Minimal short-term | Neutral | Neutral | No (off-label guideline) | | Obeticholic acid 25 mg | Pruritus (51%), fatigue | Neutral | +20 to 30% LDL | No (NASH approval withdrawn) |

Sources for the table: [5, 9, 11, 16, 20]

Regulatory Pathway and What to Expect Next

The FDA's 2018 guidance for NASH drug development requires two independent Phase III trials each meeting both co-primary histologic endpoints, or a single trial with both endpoints and a pre-specified interim analysis. [8] Saroglitazar's U.S. Phase III trials were initiated by Zydus Lifesciences following Phase II FDA feedback. Enrollment targets approximately 700 patients at F2, F3 fibrosis. If the trials begin enrollment in 2024, a readout is plausible by 2027 to 2028.

The FDA also permits accelerated approval based on a single well-controlled trial if a surrogate endpoint is reasonably likely to predict clinical benefit. Resmetirom used this pathway with histology as a surrogate. Saroglitazar may pursue the same route, which could shorten the timeline by 12 to 18 months relative to a full outcomes trial. [8]